Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 8;13(2):218.
doi: 10.3390/antiox13020218.

Sustained Systemic Antioxidative Effects of Intermittent Theta Burst Stimulation beyond Neurodegeneration: Implications in Therapy in 6-Hydroxydopamine Model of Parkinson's Disease

Affiliations

Sustained Systemic Antioxidative Effects of Intermittent Theta Burst Stimulation beyond Neurodegeneration: Implications in Therapy in 6-Hydroxydopamine Model of Parkinson's Disease

Milica Zeljkovic Jovanovic et al. Antioxidants (Basel). .

Abstract

Parkinson's disease (PD) is manifested by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and caudoputamen (Cp), leading to the development of motor and non-motor symptoms. The contribution of oxidative stress to the development and progression of PD is increasingly recognized. Experimental models show that strengthening antioxidant defenses and reducing pro-oxidant status may have beneficial effects on disease progression. In this study, the neuroprotective potential of intermittent theta burst stimulation (iTBS) is investigated in a 6-hydroxydopamine (6-OHDA)-induced PD model in rats seven days after intoxication which corresponds to the occurrence of first motor symptoms. Two-month-old male Wistar rats were unilaterally injected with 6-OHDA to mimic PD pathology and were subsequently divided into two groups to receive either iTBS or sham stimulation for 21 days. The main oxidative parameters were analyzed in the caudoputamen, substantia nigra pars compacta, and serum. iTBS treatment notably mitigated oxidative stress indicators, simultaneously increasing antioxidative parameters in the caudoputamen and substantia nigra pars compacta well after 6-OHDA-induced neurodegeneration process was over. Serum analysis confirmed the systemic effect of iTBS with a decrease in oxidative markers and an increase in antioxidants. Prolonged iTBS exerts a modulatory effect on oxidative/antioxidant parameters in the 6-OHDA-induced PD model, suggesting a potential neuroprotective benefit, even though at this specific time point 6-OHDA-induced oxidative status was unaltered. These results emphasize the need to further explore the mechanisms of iTBS and argue in favor of considering it as a therapeutic intervention in PD and related neurodegenerative diseases.

Keywords: 6-hydroxidopamine; Parkinson’s disease; intermittent theta burst stimulation; neuroprotection; oxidative stress; rTMS.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Unilateral 6-OHDA lesion induces motor impairment. Histograms showing latency to fall (A) and distance travelled (B) on a rotarod test of animals before (pre-intoxication) and 7-days after 6-OHDA unilateral lesion (7 dpi). All data are represented as mean ± SD. Dots in the graphs represent individual values. Number in the bottom of the graphs represents number of individual animals included in analysis. Results of post hoc Tukey’s test and significance are shown inside graphs: **** p < 0.0001.
Figure 2
Figure 2
Effects of prolonged iTBS treatment on oxidative balance in the caudoputamen of 6-OHDA-induced model of PD. Spectrophotometric analysis of pro-oxidative and enzymatic/non-enzymatic antioxidative parameters: (A) MDA, O2•−, NO; (B) total SOD, CAT; (C) GSH and SH levels measured in caudoputamen homogenates (left and right hemisphere) from sham and iTBS animals after three weeks of stimulation. Bars shows mean activity expressed as U/mg protein or mol/mg protein. All data are presented as mean ± SD. Number in the bottom of the graphs represent number of individual animals included in analysis. Results of post hoc Tukey’s test and significance are shown inside graphs: ns–not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 3
Figure 3
Effects of prolonged iTBS treatment on oxidative balance in the substantia nigra pars compacta of 6-OHDA-induced model of PD. Spectrophotometric analysis of pro-oxidative and enzymatic/non-enzymatic antioxidative parameters: (A) MDA, O2•−, NO; (B) total SOD, CAT, (C) GSH and SH levels measured in midbrain homogenates (left and right hemisphere) from sham and iTBS animals after three weeks of stimulation. Bars shows mean activity expressed as U/mg protein or mol/mg protein. All data are presented as mean ± SD. The numbers at the bottom of the graphs indicate the number of individual animals included in the analysis. Results of post hoc Tukey’s test and significance are shown inside graphs: ns—not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 4
Figure 4
Effects of prolonged iTBS treatment on oxidative balance in the serum of 6-OHDA-induced model of PD. Spectrophotometric analysis of pro-oxidative and antioxidative parameters: (A) MDA-, (B) NO-, (C) SH levels measured in blood serum of sham and iTBS animals after three weeks of stimulation. The bars show the mean activity expressed as U/mg protein or mol/mg protein. All data are presented as mean ± SD. The numbers at the bottom of the graphs indicate the number of individual animals included in the analysis. Results of post hoc Tukey’s test and significance are shown inside graphs: * p < 0.05, ** p < 0.01.

Similar articles

Cited by

References

    1. Balestrino R., Schapira A.H.V. Parkinson disease. Eur. J. Neurol. 2020;27:27–42. doi: 10.1111/ene.14108. - DOI - PubMed
    1. Tolosa E., Garrido A., Scholz S.W., Poewe W. Challenges in the diagnosis of Parkinson;s disease. Lancet Neurol. 2021;20:385–397. doi: 10.1016/S1474-4422(21)00030-2. - DOI - PMC - PubMed
    1. Nakabeppu Y., Tsuchimoto D., Yamaguchi H., Sakumi K. Oxidative damage in nucleic acids and Parkinson’s disease. J. Neurosci. Res. 2007;85:919–934. doi: 10.1002/jnr.21191. - DOI - PubMed
    1. Zeevalk G.D., Razmpour R., Bernard L.P. Glutathione and Parkinson’s disease: Is this the elephant in the room? Biomed. Pharmacother. 2008;62:236–249. doi: 10.1016/j.biopha.2008.01.017. - DOI - PubMed
    1. Hernandez-Baltazar D., Zavala-Flores L.M., Villanueva-Olivo A. The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model. El modelo de 6-hidroxidopamina y la fisiopatología parkinsoniana: Nuevos hallazgos en un viejo modelo. Neurologia. 2017;32:533–539. doi: 10.1016/j.nrl.2015.06.011. - DOI - PubMed

LinkOut - more resources